887
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors

, , &
Pages 205-211 | Received 13 Jan 2015, Accepted 27 Jan 2015, Published online: 20 Mar 2015

Figures & data

Chart 1. Structure of compounds A–D and the clinically used sulfonamide acetazolamide AAZ.

Chart 1. Structure of compounds A–D and the clinically used sulfonamide acetazolamide AAZ.

Scheme 1. Preparation of sulfonamides 6–20 by reaction of 4-amino-N-(4-sulfamoyl-benzyl)-butyramide hydrochloride (n = 1) (4) or 4-amino-N-[2-(4-sulfamoyl-phenyl)-ethyl]-butyramide hydrochloride (n = 2) (5) with arylisocyanates A1–8 (R-NCO) in presence of diisopropylethylamine (DIPEA), in acetonitrile (dry).

Scheme 1. Preparation of sulfonamides 6–20 by reaction of 4-amino-N-(4-sulfamoyl-benzyl)-butyramide hydrochloride (n = 1) (4) or 4-amino-N-[2-(4-sulfamoyl-phenyl)-ethyl]-butyramide hydrochloride (n = 2) (5) with arylisocyanates A1–8 (R-NCO) in presence of diisopropylethylamine (DIPEA), in acetonitrile (dry).

Table 1. Isocyanates used for the preparation of compounds 6–20.

Table 2. Inhibition data of human CA isoforms hCA I, II, IX and XII with ureido-sulfonamides 6–20 reported here and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped flow CO2 hydrase assayCitation26. .

Figure 1. Graphical comparison of inhibition constants of the new ureido-sulfonamides 6–20 reported here and the standard drug AAZ against hCA I, II, IX and XII.

Figure 1. Graphical comparison of inhibition constants of the new ureido-sulfonamides 6–20 reported here and the standard drug AAZ against hCA I, II, IX and XII.

Figure 2. Graphical comparison of inhibition constants of the ureido-sulfonamides A–D previously reported and the standard drug AAZ against hCA I, II, IX and XII.

Figure 2. Graphical comparison of inhibition constants of the ureido-sulfonamides A–D previously reported and the standard drug AAZ against hCA I, II, IX and XII.
Supplemental material

Supplemental Material.pdf

Download PDF (140.3 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.